Mimedx (MDXG) Current Deferred Revenue (2011 - 2012)
Mimedx recorded quarterly Current Deferred Revenue of $6620.0 in Q1 2012, little changed quarter-over-quarter from $6620.0 in Q4 2011.
Mimedx's Current Deferred Revenue history runs 2 years deep, the most recent figure standing at $6620.0 for Q1 2012.
- In Q1 2012, Current Deferred Revenue changed N/A year-over-year to $6620.0; the TTM figure through Mar 2012 stood at $6620.0 (changed N/A YoY), while the FY2011 annual figure was $6620.0, changed N/A from the prior year.
- Current Deferred Revenue came in at $6620.0 for Q1 2012 at Mimedx, roughly flat from $6620.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $6620.0 in Q2 2011 to a low of $6620.0 in Q2 2011.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Mimedx | 530.69 Mn | 370.92 Mn | 41.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2012 | 6,620.00 |
| Dec 31, 2011 | 6,620.00 |
| Sep 30, 2011 | 6,620.00 |
| Jun 30, 2011 | 6,620.00 |